Eli Lilly and Company (LLY)

NYSE: LLY · IEX Real-Time Price · USD
-1.55 (-0.47%)
Jul 7, 2022 1:15 PM EDT - Market open
Market Cap 312.22B
Revenue (ttm) 29.32B
Net Income (ttm) 6.13B
Shares Out 950.16M
EPS (ttm) 6.73
PE Ratio 48.83
Forward PE 39.06
Dividend $3.66 (1.11%)
Ex-Dividend Date Aug 12, 2022
Volume 980,710
Open 327.25
Previous Close 330.15
Day's Range 326.24 - 330.42
52-Week Range 220.20 - 332.74
Beta 0.40
Analysts Buy
Price Target 327.14 (-0.4%)
Earnings Date Aug 2, 2022

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal... [Read more...]

Industry Pharmaceuticals
Founded 1876
CEO David Ricks
Employees 35,000
Stock Exchange NYSE
Ticker Symbol LLY
Full Company Profile

Financial Performance

In 2021, LLY's revenue was $28.32 billion, an increase of 15.40% compared to the previous year's $24.54 billion. Earnings were $5.58 billion, a decrease of -9.88%.

Financial Statements

Analyst Forecast

According to 31 analysts, the average rating for LLY stock is "Buy." The 12-month stock price forecast is 327.14, which is a decrease of -0.44% from the latest price.

Price Target
(-0.44% downside)
Analyst Consensus: Buy
Stock Forecasts


As Markets Churn, These 2 Stocks Just Hit All-Time Highs

You can find winners even in today's stock market.

Other symbols: GIS

3rd-Quarter Clinical Trial Data Could Shake Up Pharma Stocks

Health care investors would be wise to keep tabs on the results of numerous drug trials scheduled to be revealed in the third quarter. Trial data can impact the stock price of a pharmaceutical company, ...


What Bear Market? These 2 Stocks Are Killing It.

What else do these companies have in store?

Other symbols: JAZZ

These 3 Stocks Might (Still) Be a Little Too Expensive

Yes, valuations still matter, and it may take further time for them to reach appropriate levels.

Other symbols: ROLTMUS

5 S&P 500 Stocks Ready to Break Out

Although Wall Street is hurting right now, not all S&P 500 stocks are getting thrashed. And these beauties are getting ready to break out.


Eli Lilly to supply another 150,000 doses of COVID treatment to the government

Eli Lilly & Co. LLY, -2.95% said Wednesday that it will supply the U.S. government with an additional 150,000 doses of its COVID treatment bebtelovimab for about $275 million. Delivery of the doses will...

Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-1...

Bebtelovimab continues to maintain neutralization against all known variants of interest and concern INDIANAPOLIS , June 29, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a modi...

All-time highs for pharma stocks: Names to trade now

Big pharma surges, and here are the names to trade. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Dan Nathan, Courtney Garcia and Karen Finerman.

Other symbols: BMYMRKXLV

7 Defensive Stocks to Buy for a Bear Market

As Wall Street gets ready for another earnings season, investors are increasingly chasing after defensive stocks to buy for a bear market. The post 7 Defensive Stocks to Buy for a Bear Market appeared f...


Lilly Declares Third-Quarter 2022 Dividend

INDIANAPOLIS , June 27, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2022 of $0.98 per share on outstanding common st...

Why Eli Lilly & Co could be a recession-proof stock

With inflation raging and the Federal Reserve (Fed) waging an epic battle against it, a recession seems on the horizon.

Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with C...

SAN FRANCISCO and SUZHOU, China, June 26, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Stocks Rebound Strongly; Exxon Mobil, Dollar General, Eli Lilly In Focus | Stock Market Today

Nice session, but market rally isn't confirmed yet. Get more IBD by subscribing to our channel: https://bit.ly/3OqppAs Visit our website: investors.com Like us on Facebook: https://www.facebook.com/inve...

Other symbols: DGXOM

Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with C...

SAN FRANCISCO, INDIANAPOLIS and SUZHOU, China, June 20, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Why Eli Lilly's Immunology Prospects Look Promising

Uplifting news turns the tide in immunology.

Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen

Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.

Other symbols: BIIB

Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata

Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Al...

INDIANAPOLIS, June 13, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitini...

Other symbols: INCY

Final Trades: ChargePoint, Eli Lilly, Sabra Health Care & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: CHPTSBRA

Stock Market Falls, Oil Prices, Bond Yields Rise; United Therapeutics, Eli Lilly, Vertex Hold Up

Higher volume resulted in a distribution day for the indexes. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market re...

Other symbols: UTHRVERX

Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One Year

Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.

Eli Lilly weight loss drug for type-2 diabetes approved by the FDA

Yahoo Finance senior health reporter Anjalee Khemlani details Eli Lilly's type-2 diabetes drug approval by the FDA for use as a weight loss drug.

Whistleblower sues Eli Lilly over drug manufacturing problems

(Reuters) -A former human resources officer at Eli Lilly and Co sued the drugmaker on Monday, alleging she was terminated after pointing out poor manufacturing practices and data falsification involving...

Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy...

80% of lebrikizumab responders maintained improvements in skin clearance and disease severity at 52 weeks; lasting improvements in itch were also observed Data supported both once every two week and onc...

New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the A...

Mounjaro led to significantly greater fat mass reductions compared to placebo and to injectable semaglutide 1 mg in adults with type 2 diabetes in mechanism of action study Exploratory analysis showed t...